Hemophilia B Gene Therapy Market Forecast Highlights Expansion From $0.71 Billion To $2.01 Billion Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Hemophilia B Gene Therapy Market Size Forecast: How Large Could The Market Become By 2030?
The hemophilia b gene therapy market has experienced considerable expansion in recent years. It is anticipated to grow from $0.55 billion in 2025 to $0.71 billion in 2026, at a compound annual growth rate (CAGR) of 29.6%. This past growth can be attributed to several factors including advances in gene delivery technologies, improved understanding of hemophilia b genetics, the broadening of clinical research programs, the escalating burden of lifelong replacement therapy, and the establishment of specialized treatment centers.
The hemophilia b gene therapy market size is projected to experience substantial growth in the coming years, with expectations to reach $2.01 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 29.8%. This expansion during the forecast period is attributed to increasing approvals of gene therapies, rising investments in rare disease treatments, a growing demand for durable therapeutic outcomes, the expansion of advanced manufacturing capabilities, and an increase in patient access programs. Major trends anticipated in this period include enhanced progress in one-time curative therapies, a greater focus on long-term factor IX expression, continuous optimization of AAV vector design, the expansion of personalized gene therapy approaches, and improved regulatory alignment for advanced therapies.
Download A Free Sample Report For Comprehensive Market Insights:
Hemophilia B Gene Therapy Market Demand Drivers: What Is Fueling Industry Growth?
The growing volume of gene therapy clinical trials is anticipated to boost the expansion of the hemophilia B gene therapy market in the future. These trials are investigative studies aimed at assessing the safety, effectiveness, and lasting therapeutic promise of gene-based treatments in human subjects. The surge in gene therapy clinical trials stems from increased capital inflow from biopharmaceutical firms, progress in viral vector technology, supportive regulatory environments, and the imperative to tackle rare genetic conditions with significant unmet medical demands, such as hemophilia B. Hemophilia B gene therapy gains advantages from this expanding field of clinical trials by utilizing existing clinical development routes, regulatory know-how, and production capabilities linked to in vivo gene delivery methods. For instance, in January 2026, according to Bioindustry Association (BIA) a UK-based national trade association, UK recorded 193 ongoing advanced therapy clinical trials, broadly similar to 2024, with over half in early stages, around 80% commercially sponsored, and more than 80% focused on gene therapies, evenly split between ex vivo and in vivo approaches. Consequently, the increasing number of cell and gene therapy clinical trials is stimulating growth in the hemophilia B gene therapy market.
Hemophilia B Gene Therapy Market Segment Breakdown: Which Categories Generate The Most Revenue?
The hemophilia b gene therapy market covered in this report is segmented –
1) By Therapy: Adeno-Associated Viral (AAV) Vectors; Lentiviral Vectors; Retroviral Vectors
2) By Disease Severity: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B
3) By Treatment Type: On-Demand; Cure; Prophylaxis
4) By Patient Age Group: Geriatric; Adults; Pediatric
5) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies
Subsegments:
1) By Adeno-Associated Viral Vectors: Single-Stranded Adeno-Associated Viral Vectors; Self-Complementary Adeno-Associated Viral Vectors; Tissue Specific Promoter Adeno-Associated Viral Vectors; Capsid Modified Adeno-Associated Viral Vectors
2) By Lentiviral Vectors: Integrating Lentiviral Vectors; Non-Integrating Lentiviral Vectors; Self-Inactivating Lentiviral Vectors; Pseudotyped Lentiviral Vectors
3) By Retroviral Vectors: Gamma Retroviral Vectors; Alpha Retroviral Vectors; Moloney Murine Leukemia Virus Retroviral Vectors; Spumaretroviral Vectors
Hemophilia B Gene Therapy Market Innovation Trends: Which Developments Are Transforming The Industry?
Leading companies in the hemophilia B gene therapy market are increasingly prioritizing innovations in advanced gene delivery platforms, particularly optimized adeno-associated virus (AAV)–based vector systems, to enhance treatment effectiveness and patient safety. These refined AAV-based vector systems function as sophisticated viral delivery mechanisms, enabling the efficient and controlled transfer of functional clotting factor IX genes into target hepatocytes, thereby supporting long-term endogenous factor production. For instance, in May 2023, CSL Behring GmbH, a Germany-based biotechnology company, obtained European Commission approval for HEMGENIX, which is the first gene therapy authorized for the treatment of hemophilia B. HEMGENIX is prescribed for adult patients with severe or moderate hemophilia B who do not have a history of factor IX inhibitors and is designed to reduce or eliminate the requirement for routine factor IX prophylaxis. Results from the pivotal HOPE-B clinical study showed that a significant number of treated patients no longer needed regular factor IX infusions, demonstrating a sustained therapeutic benefit and emphasizing the potential of next-generation AAV-based gene therapies in long-term disease management.
Hemophilia B Gene Therapy Market Key Players And Strategic Industry Positioning
Major companies operating in the hemophilia b gene therapy market are REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.
Access The Complete Hemophilia B Gene Therapy Market Report:
Hemophilia B Gene Therapy Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the hemophilia b gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia b gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
